THERAVANCE BIOPHARMA INC (TBPH) Stock Price, Forecast & Analysis
USA - NASDAQ:TBPH - KYG8807B1068 - Common Stock
TBPH Key Statistics, Chart & Performance
The current stock price of TBPH is 17.81 USD. In the past month the price increased by 26.64%. In the past year, price increased by 87.22%.
TBPH Latest News, Press Relases and Analysis
TBPH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.5 | 988.62B | ||
| JNJ | JOHNSON & JOHNSON | 19.59 | 489.83B | ||
| MRK | MERCK & CO. INC. | 10.69 | 235.34B | ||
| PFE | PFIZER INC | 7.6 | 138.36B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.95 | 92.80B | ||
| ZTS | ZOETIS INC | 18.39 | 51.66B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.28 | 22.25B | ||
| VTRS | VIATRIS INC | 4.41 | 11.97B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.13 | 10.55B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.16 | 7.90B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.23B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 3.69B |
Related stock screener links
About TBPH
Company Profile
Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. The company is headquartered in George Town, Grand Cayman and currently employs 97 full-time employees. The company went IPO on 2014-05-16. The firm operates through a single segment, namely, development and commercialization of human therapeutics. Its product, YUPELRI (revefenacin) inhalation solution, is a nebulized long-acting muscarinic antagonist used for the treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in the lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Its Ampreloxetine, is a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy.
Company Info
THERAVANCE BIOPHARMA INC
Ugland House, South Church Street
GEORGE TOWN GRAND CAYMAN KY1-1104 KY
CEO: Rick E Winningham
Employees: 97
Phone: 16508086000
THERAVANCE BIOPHARMA INC / TBPH FAQ
What does TBPH do?
Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. The company is headquartered in George Town, Grand Cayman and currently employs 97 full-time employees. The company went IPO on 2014-05-16. The firm operates through a single segment, namely, development and commercialization of human therapeutics. Its product, YUPELRI (revefenacin) inhalation solution, is a nebulized long-acting muscarinic antagonist used for the treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in the lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Its Ampreloxetine, is a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy.
Can you provide the latest stock price for THERAVANCE BIOPHARMA INC?
The current stock price of TBPH is 17.81 USD. The price increased by 0.45% in the last trading session.
Does THERAVANCE BIOPHARMA INC pay dividends?
TBPH does not pay a dividend.
What is the ChartMill rating of THERAVANCE BIOPHARMA INC stock?
TBPH has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the Price/Earnings (PE) ratio of THERAVANCE BIOPHARMA INC (TBPH)?
THERAVANCE BIOPHARMA INC (TBPH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.05).
Can you provide the growth outlook for THERAVANCE BIOPHARMA INC?
The Revenue of THERAVANCE BIOPHARMA INC (TBPH) is expected to grow by 80.96% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the Short Interest ratio of THERAVANCE BIOPHARMA INC (TBPH) stock?
The outstanding short interest for THERAVANCE BIOPHARMA INC (TBPH) is 10.57% of its float.
TBPH Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to TBPH. When comparing the yearly performance of all stocks, TBPH is one of the better performing stocks in the market, outperforming 94.67% of all stocks.
TBPH Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to TBPH. TBPH scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
TBPH Financial Highlights
Over the last trailing twelve months TBPH reported a non-GAAP Earnings per Share(EPS) of -1.05. The EPS decreased by -10.53% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 36.53% | ||
| ROA | 7.06% | ||
| ROE | 12.61% | ||
| Debt/Equity | 0.14 |
TBPH Forecast & Estimates
12 analysts have analysed TBPH and the average price target is 21.25 USD. This implies a price increase of 19.31% is expected in the next year compared to the current price of 17.81.
For the next year, analysts expect an EPS growth of 186.4% and a revenue growth 80.96% for TBPH